Tropisetron (Navoban)

An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.

Also Known As:

Navoban; (3 alpha-Tropanyl)-1H-indole-3-carboxylic Acid Ester; ICS 205-930; ICS-205-930; ICS-205930; Indole-3-carboxylic Acid Tropine Ester; Tropisetron Hydrochloride; ICS 205 930; ICS 205930; Indole 3 carboxylic Acid Tropine Ester; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-

Networked: 467 relevant articles (127 outcomes, 136 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Tropisetron: 467

Experts

1.	Müller, W: 22 articles (10/2006 - 01/2000)
2.	Stratz, T: 18 articles (10/2006 - 01/2000)
3.	Dehpour, Ahmad Reza: 11 articles (04/2021 - 05/2011)
4.	Färber, L: 10 articles (01/2004 - 01/2000)
5.	Hashimoto, Kenji: 9 articles (07/2015 - 07/2005)
6.	Späth, M: 9 articles (01/2004 - 01/2000)
7.	Rahimian, Reza: 8 articles (09/2020 - 05/2011)
8.	Naderi, Roya: 7 articles (08/2021 - 02/2020)
9.	Haus, U: 7 articles (01/2004 - 01/2000)
10.	Barzegar-Fallah, Anita: 5 articles (10/2021 - 05/2011)

Related Diseases

1.	Vomiting 01/01/1994 - "Tropisetron at doses of at least 0.20 mg/kg was significantly more effective in preventing vomiting than lower tropisetron doses or placebo, both in terms of treatment failure (> four vomits) (P = 0.015) and patient and investigator efficacy ratings (P = 0.04 for investigator rating; P = 0.035 for patient rating). " 10/01/1994 - "Improved control of emesis also was observed over 4 consecutive days of follow-up in the tropisetron group. " 02/01/1995 - "The role of Navoban for delayed emesis must be evaluated in future trials. " 11/01/1994 - "In this study failures ( > 3 vomiting) were rescued with a second infusion of tropisetron (5-mg fixed dose). " 08/01/2021 - "During the first time of the mFOLFOX6 regimen, the patient had severe side effects of vomiting, despite tropisetron being routinely given. "
2.	Nausea 10/01/2011 - "By 60 min and thereafter, the decrease in nausea score from baseline was greater (although not significantly so) in the tropisetron group. " 02/01/2006 - "However, tropisetron reduced post-operative nausea." 02/01/2006 - "In the post-operative questionnaire, the patients reported less post-operative nausea in the tropisetron group than in the placebo group (P < 0.01). " 09/01/1998 - "On Day 3, complete protection from nausea was achieved in 65% of patients receiving tropisetron and in 51% of patients receiving placebo (P = 0.0304). " 02/01/1996 - "The incidence of nausea was 30% (12/40) in the tropisetron group and 52% (21/40) in the placebo group (P < 0.05). "
3.	Postoperative Nausea and Vomiting (PONV) 10/01/1998 - "We conclude that single-dose tropisetron 5 mg is more effective than tropisetron 2 mg in the prevention of PONV after breast surgery. " 10/01/1998 - "In this randomized, double-blind, placebo-controlled study, we compared the efficacy of tropisetron 5 mg with tropisetron 2 mg for the prevention of postoperative nausea and vomiting (PONV) after breast surgery. " 01/01/1996 - "In a prospective, randomized, multicentre, double-blind, placebo-controlled study, we have compared the efficacy of a single i.v. dose of tropisetron 0.5 mg, 2 mg and 5 mg in the prevention of postoperative nausea and vomiting (PONV). " 12/01/2006 - "The incidence of postoperative vomiting (POV) was statistically more significant in the placebo group at 2, 6 and 24 hours, when compared to the study groups (p< 0.001), but there was no significant difference among tropisetron groups at 6-24 hours (p>0.05). " 04/01/2006 - "The aim of the study was to compare the effects of early vs late intraoperative administration of tropisetron with regard to prevention of PONV during the first 48 h after extubation. "
4.	Neoplasms (Cancer) 04/01/2020 - "A literature search of the EMBASE and PubMed databases was performed to identify publications of intravenous (IV) tropisetron (generic forms or Navoban®) for the treatment of CINV in patients with various cancers. " 07/01/2016 - "Our results showed that tumor development in tropisetron-treated CAC group was significantly lower than the controls. " 09/01/2008 - "The acute effect of tropisetron on ECG parameters in cancer patients." 09/01/1995 - "Tropisetron was given to 15 children (8 boys and 7 girls, ranging from 6 months to 17 years of age) with miscellaneous neoplasms. " 08/01/1994 - "Tropisetron was given to 15 children (eight boys and seven girls 18 months to 18 years of age) with miscellaneous neoplasms. "
5.	Fibromyalgia (Fibrositis) 01/01/2004 - "Although tropisetron proved to be efficacious in a group of fibromyalgia patients, the dose-response curves cannot yet be explained in a fully satisfactory manner, which may encourage research focusing on possible subgroups of FM." 01/01/2001 - "Short-term treatment of fibromyalgia patients with 5 mg tropisetron for 10 days proved to be efficacious and well tolerated. " 01/01/2000 - "We conclude that administration of tropisetron in fibromyalgia patients could be useful in the management of this difficult and incurable syndrome." 01/01/2000 - "This study demonstrates the efficacy of short-term treatment with 5 mg tropisetron once daily in primary fibromyalgia. " 01/01/2004 - "Previous studies evaluating the efficacy and tolerance of tropisetron for the treatment of fibromyalgia (FM) used the drug either intravenously or orally, and at different dosage levels ranging from 2 mg to 15 mg daily. "

Related Drugs and Biologics

1.	Ondansetron (Zofran)
2.	Dexamethasone (Maxidex)
3.	Antiemetics
4.	Cisplatin (Platino)
5.	Granisetron (Kytril)
6.	Tropisetron (Navoban)
7.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
8.	Serotonin (5 Hydroxytryptamine)
9.	Metoclopramide (Reglan)
10.	dolasetron (Anzemet)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Tonsillectomy
3.	Therapeutics
4.	Laparoscopic Cholecystectomy
5.	Anesthesia